The National Institute of Health and Care Excellence (NICE) have published new or updated guidance for the month of July 2019. This month there are four guidelines that impact upon primary care.
The Suspected neurological conditions guideline has been updated. It covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation. The update changed the timing of referral from urgent to immediate for adults with sudden-onset speech or language disturbance and children under 4 years with a change in head circumference and signs or symptoms of raised intracranial pressure following user feedback.
The Long-acting reversible contraception guideline has been updated. It covers long-acting reversible contraception. It aims to increase the use of long-action reversible contraception by improving the information given to women about their contraceptive choices. The update notes the wider range of LARC products now available and recognises the different ways contraceptive services are commissioned and provided in England.
The Neuropathic pain in adults: pharmacological management in non-specialist settings guideline has been updated. It covers managing neuropathic pain with pharmacological treatments in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management. The update has amended footnotes reflecting the legal status of gabapentin and pregabalin.
The Motor neurone disease: assessment and management guideline has been updated. It covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care. The update has amended footnotes reflecting the legal status of gabapentin and pregabalin.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.